WO2015047510A1 - Conjugués anticorps anti-trop-2-médicament et leurs utilisations - Google Patents

Conjugués anticorps anti-trop-2-médicament et leurs utilisations Download PDF

Info

Publication number
WO2015047510A1
WO2015047510A1 PCT/US2014/045074 US2014045074W WO2015047510A1 WO 2015047510 A1 WO2015047510 A1 WO 2015047510A1 US 2014045074 W US2014045074 W US 2014045074W WO 2015047510 A1 WO2015047510 A1 WO 2015047510A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
trop
cancer
seq
drug
Prior art date
Application number
PCT/US2014/045074
Other languages
English (en)
Inventor
Serengulam V. Govindan
David M. Goldenberg
Original Assignee
Immunomedics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/040,024 external-priority patent/US8758752B2/en
Priority claimed from US14/258,228 external-priority patent/US9138485B2/en
Application filed by Immunomedics, Inc. filed Critical Immunomedics, Inc.
Priority to EP14847616.1A priority Critical patent/EP3049443A4/fr
Priority to CA2920192A priority patent/CA2920192A1/fr
Publication of WO2015047510A1 publication Critical patent/WO2015047510A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions et des méthodes d'utilisation de conjugués anticorps-médicament (ADC) comprenant un anticorps anti-Trop-2 ou un fragment de celui-ci se liant à l'antigène, conjugué à un ou à plusieurs médicaments cytotoxiques. De préférence, l'anticorps est un anticorps RS7, 162-46.2 ou MAB650, de préférence, humanisé. De préférence le médicament est un SN-38, une pro-2-pyrrolino-doxorubicine, le paclitaxel, la calichemicine, un DM1, DM3, DM4, MMAE, MMAD ou MMAF. Les compositions et les méthodes selon l'invention sont utiles pour traiter les cancers exprimant Trop-2, tels que le cancer du sein, de l'ovaire, du col de l'utérus, de l'endomètre, du poumon, de la prostate, du côlon, de l'estomac, de l'œsophage, de la vessie, du rein, du pancréas, de la thyroïde, de l'épithélium ou de la tête et du cou. De préférence, le cancer est un cancer résistant à une ou plusieurs thérapies anticancéreuses standards. De préférence encore, l'anticorps anti-Trop-2 se lie à la protéine Trop-2 exprimée à la surface de cellules normales, mais l'administration de l'ADC anti-Trop-2 à des patients humains atteints de cancer à une dose thérapeutiquement efficace ne produit qu'une toxicité limitée.
PCT/US2014/045074 2013-09-27 2014-07-01 Conjugués anticorps anti-trop-2-médicament et leurs utilisations WO2015047510A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14847616.1A EP3049443A4 (fr) 2013-09-27 2014-07-01 Conjugués anticorps anti-trop-2-médicament et leurs utilisations
CA2920192A CA2920192A1 (fr) 2013-09-27 2014-07-01 Conjugues anticorps anti-trop-2-medicament et leurs utilisations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14/040,024 2013-09-27
US14/040,024 US8758752B2 (en) 2002-03-01 2013-09-27 RS7 antibodies
US14/258,228 US9138485B2 (en) 2002-12-13 2014-04-22 Immunoconjugates with an intracellularly-cleavable linkage
US14/258,228 2014-04-22
US14/259,469 2014-04-23
US14/259,469 US9833511B2 (en) 2002-03-01 2014-04-23 RS7 antibodies

Publications (1)

Publication Number Publication Date
WO2015047510A1 true WO2015047510A1 (fr) 2015-04-02

Family

ID=52744758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/045074 WO2015047510A1 (fr) 2013-09-27 2014-07-01 Conjugués anticorps anti-trop-2-médicament et leurs utilisations

Country Status (3)

Country Link
EP (1) EP3049443A4 (fr)
CA (1) CA2920192A1 (fr)
WO (1) WO2015047510A1 (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087651A1 (fr) * 2014-12-04 2016-06-09 Emanuela Guerra Anticorps monoclonaux anti-pré-trop-2 humanisés et leurs utilisations
WO2016172427A1 (fr) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, détection, diagnostic et/ou caractérisation de cellules cancéreuses trop-2 positives
WO2016210108A1 (fr) 2015-06-25 2016-12-29 Immunomedics, Inc. Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer
CN106729743A (zh) * 2015-11-23 2017-05-31 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107674051A (zh) * 2017-09-20 2018-02-09 南京医科大学 4‑羟基他莫昔酚环状衍生物乏氧活化前药及其药物用途
WO2018036438A1 (fr) * 2016-08-23 2018-03-01 四川科伦博泰生物医药股份有限公司 Conjugué anticorps-médicament et son procédé de préparation et d'application
CN108066772A (zh) * 2016-11-14 2018-05-25 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
CN109310385A (zh) * 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US10422788B2 (en) 2016-12-19 2019-09-24 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP2020503243A (ja) * 2017-08-11 2020-01-30 バイオ − テラ ソリューションズ、リミテッド Ｔｒｏｐ２陽性疾患の治療のための化合物及び方法
US10562925B2 (en) 2015-05-18 2020-02-18 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
WO2020016662A3 (fr) * 2018-07-09 2020-04-02 Abmart Inc. Anticorps spécifiques de l'antigène trophoblaste 2 (trop2)
US10624880B2 (en) 2015-04-20 2020-04-21 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
US10668167B2 (en) 2016-06-02 2020-06-02 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
EP3600283A4 (fr) * 2017-03-27 2020-12-16 Immunomedics, Inc. Traitement de cancer du sein triple négatif exprimant la trop-2 avec du sacmuzumab govitécan et un inhibiteur de rad51
CN112390885A (zh) * 2019-08-12 2021-02-23 凯惠科技发展(上海)有限公司 一种trop2抗体及其制备方法、其偶联物和应用
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2021136483A1 (fr) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. Anticorps anti-trop2, conjugués anticorps-médicament, et application de ceux-ci
WO2021147993A1 (fr) * 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 Conjugué anticorps anti-trop-2-analogue d'exatécan et son utilisation médicale
WO2021188896A1 (fr) * 2020-03-20 2021-09-23 Immunomedics, Inc. Biomarqueurs pour une thérapie par sacituzumab govitécan
CN113480651A (zh) * 2021-07-19 2021-10-08 华东师范大学 一种靶向人cd133的纳米抗体及其制备方法和应用
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
IT202000031838A1 (it) * 2020-12-22 2022-06-22 Saverio Alberti Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
WO2022222992A1 (fr) * 2021-04-23 2022-10-27 Biosion Inc. Anticorps se liant à trop2 et utilisations associées
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
US11639397B2 (en) 2011-08-23 2023-05-02 Roche Glycart Ag Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2024012566A3 (fr) * 2022-07-15 2024-03-14 Genequantum Healthcare (Suzhou) Co., Ltd. Anticorps, lieurs, charge utile, conjugués et leurs applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220758A1 (en) * 2002-02-06 2005-10-06 Hans-Peter Zobel Lyophilised preparation comprising immunocytokines
US20110070156A1 (en) * 2002-06-14 2011-03-24 Immunomedics, Inc. Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy
US20110274704A1 (en) * 2004-02-13 2011-11-10 Ibc Pharmaceuticals, Inc. Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360567C (zh) * 2002-03-01 2008-01-09 免疫医疗公司 Rs7抗体
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
PT3903829T (pt) * 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
US9107960B2 (en) * 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220758A1 (en) * 2002-02-06 2005-10-06 Hans-Peter Zobel Lyophilised preparation comprising immunocytokines
US20110070156A1 (en) * 2002-06-14 2011-03-24 Immunomedics, Inc. Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy
US20110274704A1 (en) * 2004-02-13 2011-11-10 Ibc Pharmaceuticals, Inc. Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARDILLO ET AL.: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLIN CANCER RES., vol. 17, 3 March 2011 (2011-03-03), pages 3157 - 3169, XP055044596 *
CUNNINGHAM ET AL.: "Cetuximab Monotherapy and Cetuximab plus Irinotecan in lrinotecan-Refractory Metastatic Colorectal Cancer", N ENGL J MED, vol. 351, 2004, pages 337 - 45, XP008075821 *
EDELMAN ET AL.: "The Covalent Structure of an Entire yG Immunoglobulin Molecule", PROC. NATL ACAD. SCI., vol. 63, 1 May 1969 (1969-05-01), pages 78 - 85, XP055188533 *
GOVINDAN ET AL.: "New Antibody Conjugates in Cancer Therapy", THE SCIENTIFIC WORLD JOURNAL, vol. 10, 12 October 2010 (2010-10-12), pages 2070 - 2089, XP055319602 *
See also references of EP3049443A4 *

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988539B2 (en) 2005-03-03 2021-04-27 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US11639397B2 (en) 2011-08-23 2023-05-02 Roche Glycart Ag Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10501555B2 (en) 2014-12-04 2019-12-10 Abruzzo Theranostic S.R.L. Humanized anti-trop-2 monoclonal antibodies and uses thereof
WO2016087651A1 (fr) * 2014-12-04 2016-06-09 Emanuela Guerra Anticorps monoclonaux anti-pré-trop-2 humanisés et leurs utilisations
US10624880B2 (en) 2015-04-20 2020-04-21 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
CN107428837A (zh) * 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
WO2016172427A1 (fr) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolement, détection, diagnostic et/ou caractérisation de cellules cancéreuses trop-2 positives
US10436788B2 (en) 2015-04-22 2019-10-08 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP2018517888A (ja) * 2015-04-22 2018-07-05 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
EP3286224A4 (fr) * 2015-04-22 2018-11-14 Immunomedics, Inc. Isolement, détection, diagnostic et/ou caractérisation de cellules cancéreuses trop-2 positives
US10562925B2 (en) 2015-05-18 2020-02-18 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
JP2018520140A (ja) * 2015-06-25 2018-07-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
EP3313443A4 (fr) * 2015-06-25 2019-01-23 Immunomedics, Inc. Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer
JP2021185187A (ja) * 2015-06-25 2021-12-09 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
AU2016281622C1 (en) * 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AU2016281622B2 (en) * 2015-06-25 2021-07-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107735104B (zh) * 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
CN114796500A (zh) * 2015-06-25 2022-07-29 免疫医疗公司 组合抗trop-2抗体与微管抑制剂、parp抑制剂使癌症治疗结果显著改善
CN107735104A (zh) * 2015-06-25 2018-02-23 免疫医疗公司 组合抗hla‑dr抗体或抗trop‑2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3‑激酶抑制剂使癌症治疗结果显著改善
US11439620B2 (en) 2015-06-25 2022-09-13 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2016210108A1 (fr) 2015-06-25 2016-12-29 Immunomedics, Inc. Combinaison d'anticorps anti-hla-dr ou anti-trop-2 avec des inhibiteurs de microtubule, des inhibiteurs de parp, des inhibiteurs de kinase de bruton ou des inhibiteurs de phosphoinositide 3-kinase améliorant considérablement un résultat thérapeutique de cancer
US10835537B2 (en) 2015-08-03 2020-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Combination therapies for treatment of cancer
US10682356B2 (en) 2015-08-03 2020-06-16 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
US11903948B2 (en) 2015-11-23 2024-02-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
CN106729743A (zh) * 2015-11-23 2017-05-31 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN109395089A (zh) * 2015-11-23 2019-03-01 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN109395089B (zh) * 2015-11-23 2022-08-12 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN109310385A (zh) * 2016-04-27 2019-02-05 免疫医疗公司 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效
US10668167B2 (en) 2016-06-02 2020-06-02 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2018036438A1 (fr) * 2016-08-23 2018-03-01 四川科伦博泰生物医药股份有限公司 Conjugué anticorps-médicament et son procédé de préparation et d'application
CN108697809A (zh) * 2016-08-23 2018-10-23 四川科伦博泰生物医药股份有限公司 一种抗体-药物偶联物及其制备方法和应用
CN108066772A (zh) * 2016-11-14 2018-05-25 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10422788B2 (en) 2016-12-19 2019-09-24 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
EP3600283A4 (fr) * 2017-03-27 2020-12-16 Immunomedics, Inc. Traitement de cancer du sein triple négatif exprimant la trop-2 avec du sacmuzumab govitécan et un inhibiteur de rad51
JP2020503243A (ja) * 2017-08-11 2020-01-30 バイオ − テラ ソリューションズ、リミテッド Ｔｒｏｐ２陽性疾患の治療のための化合物及び方法
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
CN107674051A (zh) * 2017-09-20 2018-02-09 南京医科大学 4‑羟基他莫昔酚环状衍生物乏氧活化前药及其药物用途
US10772970B2 (en) 2017-12-01 2020-09-15 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2020016662A3 (fr) * 2018-07-09 2020-04-02 Abmart Inc. Anticorps spécifiques de l'antigène trophoblaste 2 (trop2)
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11530231B2 (en) 2018-12-04 2022-12-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
CN112390885A (zh) * 2019-08-12 2021-02-23 凯惠科技发展(上海)有限公司 一种trop2抗体及其制备方法、其偶联物和应用
CN112390885B (zh) * 2019-08-12 2024-01-19 凯惠科技发展(上海)有限公司 一种trop2抗体及其制备方法、其偶联物和应用
WO2021136483A1 (fr) * 2019-12-31 2021-07-08 Genequantum Healthcare (Suzhou) Co., Ltd. Anticorps anti-trop2, conjugués anticorps-médicament, et application de ceux-ci
WO2021147993A1 (fr) * 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 Conjugué anticorps anti-trop-2-analogue d'exatécan et son utilisation médicale
EP4095148A4 (fr) * 2020-01-22 2023-07-26 Jiangsu Hengrui Medicine Co., Ltd. Conjugué anticorps anti-trop-2-analogue d'exatécan et son utilisation médicale
WO2021188896A1 (fr) * 2020-03-20 2021-09-23 Immunomedics, Inc. Biomarqueurs pour une thérapie par sacituzumab govitécan
WO2022136191A1 (fr) * 2020-12-22 2022-06-30 Saverio Alberti Plate-forme pour obtenir des anticorps monoclonaux dirigés contre des antigènes spécifiques d'une tumeur traités
WO2022136452A1 (fr) * 2020-12-22 2022-06-30 Mediterranea Theranostic Srl Plate-forme pour obtenir des anticorps monoclonaux dirigés contre des antigènes spécifiques d'une tumeur traités
IT202000031838A1 (it) * 2020-12-22 2022-06-22 Saverio Alberti Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
WO2022222992A1 (fr) * 2021-04-23 2022-10-27 Biosion Inc. Anticorps se liant à trop2 et utilisations associées
CN113480651A (zh) * 2021-07-19 2021-10-08 华东师范大学 一种靶向人cd133的纳米抗体及其制备方法和应用
WO2024012566A3 (fr) * 2022-07-15 2024-03-14 Genequantum Healthcare (Suzhou) Co., Ltd. Anticorps, lieurs, charge utile, conjugués et leurs applications

Also Published As

Publication number Publication date
EP3049443A1 (fr) 2016-08-03
EP3049443A4 (fr) 2017-04-05
CA2920192A1 (fr) 2015-04-02

Similar Documents

Publication Publication Date Title
US11116846B2 (en) Antibody-drug conjugates and uses thereof
US9770517B2 (en) Anti-Trop-2 antibody-drug conjugates and uses thereof
US10918734B2 (en) Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
AU2017257254B2 (en) Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
EP3049443A1 (fr) Conjugués anticorps anti-trop-2-médicament et leurs utilisations
US20180296689A1 (en) Neoadjuvant use of antibody-drug conjugates
US20210046185A1 (en) Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
ES2819573T3 (es) Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
US10744129B2 (en) Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CA2782194C (fr) Combinaison d'anticorps radio-marquees et de conjugues anticorps-medicament pour le traitement du cancer pancreatique
EP3024460B1 (fr) Procédé de production d'immunoconjugués anticorps-sn-38 avec un lieur cl2a
IL256150A (en) Combination of anti-hla-dr or anti-trop-2 antibodies with tube inhibitors, parp inhibitors, brothine kinase inhibitors or phosphoniocidide 3-kinase inhibitors significantly improves treatment outcome in cancer
EP2953645A1 (fr) Forme de pro-médicament (p2pdox) de la 2-pyrrolinodoxorubicine fortement puissante conjuguée à des anticorps pour la thérapie ciblée du cancer
US20170281791A1 (en) Anti-trop-2 antibody-drug conjugates and uses thereof
JP7188837B2 (ja) Ｔｒｏｐ－２を標的化するトポイソメラーゼ－ｉ阻害抗体－薬物コンジュゲート（ａｄｃ）による小細胞肺癌（ｓｃｌｃ）の療法
US20220054648A1 (en) Antibody-drug conjugates and uses thereof
US20240139324A1 (en) Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14847616

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2920192

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014847616

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014847616

Country of ref document: EP